Overview

Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)

Status:
Active, not recruiting

Trial end date:
2022-04-29

Target enrollment:

Participant gender:

Summary

This is a continuation study of Budesonide Oral Suspension (BOS) in adults and adolescents with Eosinophilic Esophagitis (EoE) who have completed participation in the SHP621-302 extension study. The purpose of this study is to see if BOS is safe and well tolerated over the long-term in adolescents and adults with EoE.

Phase:

Phase 3

Details

Lead Sponsor:

Shire

Collaborator:

Takeda Development Center Americas, Inc.

Treatments:

Budesonide